Company Announcement no. 10-2008/09 - New judgment in US litigation

The United States District Court for Southern District of California has announced that it has invalidated LMA’s patent U.S. Patent No. 7,156,000. The District Court in San Diego has therefore unambiguously sustained Ambu’s claims that Ambu have not infringed the LMA patent and that the patent is invalid. Ambu continuously maintain their counterclaims for unfair competition.
 

The judgment can be appealed to the appeal court in Washington D.C.

The announcement can be downloaded as a PDF document here. 

Contact: Lars Marcher, President and CEO, tel. +45 5136 2490, email: lm@ambu.com

Ambu develops, produces and markets diagnostic and life-supporting devices to hospitals and rescue services. Ambu has five business areas: Respiratory Care, Cardiology, Neurology, Training and Immobilization. The most important business areas are Respiratory Care, Cardiology and Neurology, and the most important products in these areas are ventilation products for artificial respiration and single-use electrodes for ECG recordings and neurophysiological examinations. Ambu’s products are sold worldwide. Exports account for 98% of sales, and sales are handled via Ambu’s foreign subsidiaries or via distributors. Ambu has approx. 1,600 employees, of whom approx. 300 work in Denmark and approx. 1,300 abroad